<DOC>
	<DOCNO>NCT00480987</DOCNO>
	<brief_summary>The goal clinical research study find high tolerable dose oxaliplatin combine fludarabine plus cytarabine give patient Acute Myeloid Leukemia ( AML ) High-Risk Myelodysplastic Syndromes ( MDS ) . Once high tolerable dose oxaliplatin drug combination find , next goal study learn safety ability drug combination control disease .</brief_summary>
	<brief_title>Oxaliplatin , Fludarabine , Cytarabine Acute Myeloid Leukemia ( AML ) High-Risk Myelodysplastic Syndromes ( MDS )</brief_title>
	<detailed_description>The Study Drugs : Cytarabine design insert Deoxyribonucleic acid ( DNA ) ( genetic material cell ) stop DNA repairing . Fludarabine design make cancer cell less able repair damage DNA . This may increase likelihood cell die . Oxaliplatin design `` program '' cell cause death leukemic cell . The Phases The Study : This research study 2 part , Phase I Phase II . The Phase I part study use test different dose level order determine high tolerable dose study drug oxaliplatin give combination cytarabine fludarabine patient AML high-risk MDS . Three ( 3 ) participant enrol dose level high tolerable dose find . The Phase II part study evaluate safety disease-control ability study drug combination ( high tolerable dose find ) order treat patient . Study Drug Administration : If find eligible take part study , give oxaliplatin needle ( intravenously -- IV ) vein 2 hour 4 day ( Days 1-4 ) row . On Day 2 , give cytarabine IV vein continuous infusion 24 hour 5 day ( Days 2-6 ) row . Starting Day 2 , give fludarabine IV vein 30 minute 5 day ( Days 2-6 ) row . In order keep dehydrate , also give IV fluid , saline ( salt solution ) , day receive study drug . If drug give outpatient basis , daily visit may take 8 hour . One ( 1 ) cycle 6 day long . The first cycle give M. D. Anderson . Each cycle repeat every 4-6 week . Depending response study drug combination , 5 cycle either M. D. Anderson outpatient basis regular physician . Your study drug dose may lower experience severe side effect . Study Visits : During treatment cycle , blood drawn ( 1 teaspoon time ) least 2-3 time week routine test . You bone marrow aspiration do Day 21 Cycle 1 week thereafter , unless clear evidence active disease . To collect bone marrow aspirate , area hip chest bone numb anesthetic , small amount bone marrow withdrawn large needle . Length Study : You remain study 6 cycle total 6 month , unless disease responding , disease get bad , experience intolerable side effect . If take study early , study doctor discus treatment option . End-of-Treatment Visit : Once complete treatment study , end-of-treatment visit . This visit include routine blood test ( 1 teaspoon drawn time ) bone marrow aspirate check status disease . If blood test show disease gotten bad , bone marrow aspirate need . Long-Term Follow-up : After last cycle treatment complete every 3 month long remission , blood drawn ( 2 teaspoon ) routine test . This investigational study . Cytarabine Food Drug Administration ( FDA ) approve commercially available treatment AML blood cancer . Fludarabine FDA approve commercially available treatment chronic lymphocytic leukemia ( CLL ) . Oxaliplatin FDA approve commercially available treatment advance colorectal cancer colon cancer . Their use combination investigational study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Histologically cytologically confirm relapsed refractory acute myeloid leukemia ( AML ) highrisk myelodysplastic syndrome . Performance status 02 ( Zubrod scale ) . Serum creatinine equal less 1.3 mg/dL creatinine clearance &gt; 40 mL/min . Bilirubin &lt; /= 2 mg/dL ; serum glutamic oxaloacetic transaminase ( SGOT ) Serum glutamic pyruvic transaminase ( SGPT ) &lt; /= 3 time Upper Limit Normal ( ULN ) reference lab unless due leukemia congenital hemolytic disorder ( bilirubin ) . Written informed consent . No untreated uncontrolled lifethreatening infection . No oxaliplatin , fludarabine , cytarabine intolerance . No pregnancy lactation . Female patient childbearing potential ( include &lt; 1 year postmenopausal ) male patient must agree use contraception . No chemotherapy radiation therapy within 4 week study entry . Hydroxyurea allow prior start therapy set rapidly proliferate disease . No medical condition , include mental illness substance abuse , deem Investigator likely interfere patient 's ability sign inform consent cooperate participate study interfere interpretation result .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>High-Risk Myelodysplastic Syndromes</keyword>
	<keyword>Acute Myeloid Leukemia</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>AML</keyword>
	<keyword>MDS</keyword>
</DOC>